GRI Bio Participates in Virtual Investor KOL Connect Segment
GRI Bio (NASDAQ: GRI) recently participated in a Virtual Investor KOL Connect segment, featuring Albert Agro, PhD, CMO of GRI Bio, and Dr. Helen Parfrey, a prominent expert in Idiopathic Pulmonary Fibrosis (IPF). The discussion focused on IPF, current patient experiences, and GRI Bio's lead program, GRI-0621. This small molecule RAR-βɣ dual agonist inhibits iNKT cell activity and has shown promise in improving fibrosis and inflammation markers in preliminary trials.
GRI Bio is advancing GRI-0621 through a Phase 2a biomarker study, with interim data expected in Q4 2024 and topline data in Q1 2025. The company aims to address the limitations of current IPF treatments, which have significant side effects and impact on overall survival. GRI-0621 represents a potential new therapeutic approach to halt disease progression in fibrotic diseases like IPF.
GRI Bio (NASDAQ: GRI) ha recentemente partecipato a un segmento Virtual Investor KOL Connect, con Albert Agro, PhD, CMO di GRI Bio, e Dr. Helen Parfrey, un esperto di spicco nella Fibrosi Polmonare Idiopatica (IPF). La discussione si è concentrata sull'IPF, sulle esperienze attuali dei pazienti e sul programma principale di GRI Bio, GRI-0621. Questo piccolo agonista molecolare duale RAR-βɣ inibisce l'attività delle cellule iNKT e ha dimostrato di avere potenzialità nel migliorare i marcatori di fibrosi e infiammazione in studi preliminari.
GRI Bio sta portando avanti GRI-0621 tramite uno studio biomarcatori di Fase 2a, con dati intermedi attesi nel Q4 2024 e dati conclusivi nel Q1 2025. L'azienda mira a affrontare le limitazioni dei trattamenti attuali per l'IPF, che presentano effetti collaterali significativi e un impatto sulla sopravvivenza complessiva. GRI-0621 rappresenta un potenziale nuovo approccio terapeutico per fermare la progressione della malattia in malattie fibrotiche come l'IPF.
GRI Bio (NASDAQ: GRI) participó recientemente en un segmento de Virtual Investor KOL Connect, con Albert Agro, PhD, CMO de GRI Bio, y Dr. Helen Parfrey, una destacada experta en Fibrosis Pulmonar Idiopática (IPF). La discusión se centró en la IPF, las experiencias actuales de los pacientes y el programa líder de GRI Bio, GRI-0621. Este pequeño agonista dual de RAR-βɣ inhibe la actividad de las células iNKT y ha mostrado promesa para mejorar los marcadores de fibrosis e inflamación en ensayos preliminares.
GRI Bio está avanzando GRI-0621 a través de un estudio de biomarcadores de Fase 2a, con datos intermedios esperados para Q4 2024 y datos finales en Q1 2025. La empresa busca abordar las limitaciones de los tratamientos actuales para la IPF, que tienen efectos secundarios significativos y un impacto en la supervivencia general. GRI-0621 representa un posible nuevo enfoque terapéutico para detener la progresión de la enfermedad en enfermedades fibrosas como la IPF.
GRI Bio (NASDAQ: GRI)는 최근 GRI Bio의 CMO인 Albert Agro 박사와 호흡기 질환 전문가 Dr. Helen Parfrey가 참여한 가상 투자 KOL 연결 세그먼트에 참석했습니다. 논의는 IPF, 현재 환자 경험 및 GRI Bio의 주요 프로그램인 GRI-0621에 초점을 맞췄습니다. 이 작은 분자 RAR-βɣ 이중 작용제는 iNKT 세포 활동을 억제하며, 초기 시험에서 섬유증과 염증 지표를 개선하는 데 있어 가능성을 보여주었습니다.
GRI Bio는 2a상 바이오마커 연구를 통해 GRI-0621을 발전시키고 있으며, 임시 데이터는 2024년 4분기에 예상되며, 최고 데이터는 2025년 1분기에 공개될 예정입니다. 이 회사는 현행 IPF 치료법의 한계를 해결하고자 하며, 이는 상당한 부작용과 전체 생존에 영향을 미칩니다. GRI-0621은 IPF와 같은 섬유성 질환의 진행을 중단시키기 위한 잠재적인 새로운 치료 접근 방식을 나타냅니다.
GRI Bio (NASDAQ: GRI) a récemment participé à un segment Virtual Investor KOL Connect, avec Albert Agro, PhD, CMO de GRI Bio, et Dr. Helen Parfrey, une experte de renom en Fibrose Pulmonaire Idiopathique (IPF). La discussion s'est concentrée sur l'IPF, les expériences actuelles des patients et le programme phare de GRI Bio, GRI-0621. Ce petit agoniste moléculaire dual RAR-βɣ inhibe l'activité des cellules iNKT et a montré des promesses pour améliorer les marqueurs de fibrose et d'inflammation lors d'essais préliminaires.
GRI Bio fait progresser GRI-0621 à travers une étude de biomarqueurs de Phase 2a, avec des données intermédiaires attendues pour le Q4 2024 et des données finales pour le Q1 2025. L'entreprise vise à remédier aux limitations des traitements actuels de l'IPF, qui ont des effets secondaires significatifs et un impact sur la survie globale. GRI-0621 représente une nouvelle approche thérapeutique potentielle pour stopper la progression de la maladie dans des maladies fibroses comme l'IPF.
GRI Bio (NASDAQ: GRI) nahm kürzlich an einem Virtual Investor KOL Connect-Segment teil, mit Albert Agro, PhD, CMO von GRI Bio, und Dr. Helen Parfrey, einer prominenten Expertin für idiopathische Lungenfibrose (IPF). Die Diskussion konzentrierte sich auf IPF, die aktuellen Patientenerfahrungen und das führende Programm von GRI Bio, GRI-0621. Dieses kleine duale Agonistmolekül RAR-βɣ hemmt die Aktivität von iNKT-Zellen und hat in ersten Studien vielversprechende Ergebnisse zur Verbesserung der Fibrose- und Entzündungsmarker gezeigt.
GRI Bio bringt GRI-0621 durch eine Phase 2a-Biomarkerstudie voran, wobei vorläufige Daten für Q4 2024 und endgültige Daten für Q1 2025 erwartet werden. Das Unternehmen zielt darauf ab, die Einschränkungen der bestehenden IPF-Behandlungen zu adressieren, die signifikante Nebenwirkungen und Auswirkungen auf die Gesamtüberlebensrate haben. GRI-0621 stellt einen potenziellen neuen therapeutischen Ansatz dar, um das Fortschreiten der Krankheit bei fibrotischen Erkrankungen wie IPF zu stoppen.
- GRI Bio's lead program GRI-0621 has shown improvement in fibrosis and inflammation markers in preliminary trials
- Phase 2a biomarker study for GRI-0621 is ongoing with interim data expected in Q4 2024 and topline data in Q1 2025
- GRI-0621 aims to address limitations of current IPF treatments, potentially offering a new therapeutic approach
- None.
Albert Agro, PhD, CMO of GRI Bio recently participated in a Virtual Investor KOL Connect segment with prominent key opinion leader in Idiopathic Pulmonary Fibrosis (IPF) – Dr. Helen Parfrey, Respiratory Consultant at the Royal Papworth Hospital and Affiliated Assistant Professor at the University of Cambridge
Company advancing GRI-0621 toward interim data readout of Phase 2a biomarker study in Q4 2024 and topline data in Q1 2025
LA JOLLA, CA, Sept. 18, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced its participation in a recent Virtual Investor KOL Connect segment.
As part of the segment, Albert Agro, PhD, Chief Medical Officer of GRI Bio and Dr. Helen Parfrey, Respiratory Consultant at Royal Papworth Hospital and Affiliated Assistant Professor at the University of Cambridge, discuss IPF, the current patient journey, and how the Company is working to advance their lead program, GRI-0621, as a potential therapeutic solution that halts disease progression of fibrotic diseases such as IPF.
IPF is a rare chronic progressive pulmonary disease with abnormal scarring of the lung blocking the movement of oxygen into the bloodstream. Currently available treatments for IPF are limited with only two approved drugs that come with significant side-effects, limited compliance and no impact on overall survival1 leaving significant opportunity to augment IPF treatment with a new therapeutic.
GRI Bio’s lead program, GRI-0621, is a small molecule RAR-βɣ dual agonist that inhibits the activity of human iNKT cells. In preliminary trials to date and previous trials with the oral formulation, GRI-0621 has been shown to improve fibrosis in multiple disease models and improve liver function tests and other markers of inflammation and injury in patients. GRI-0621 is currently being evaluated in a Phase 2a biomarker study and expects to report interim data in Q4 2024 and topline data in Q1 2025.
About GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 invariant (iNKT) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions. These forward-looking statements are based on the Company’s current beliefs and expectations. Forward-looking statements include, but are not limited to, statements regarding: the Company’s expectations with respect to development and commercialization of the Company’s product candidates, the timing of initiation or completion of clinical trials and availability of resulting data, the potential benefits and impact of the Company’s clinical trials and product candidates and any implication that the data or results observed in preclinical trials or earlier studies or trials will be indicative of results of later studies or clinical trials, the Company’s beliefs and expectations regarding potential stakeholder value and future financial performance, the Company’s beliefs about the timing and outcome of regulatory approvals and potential regulatory approval pathways, the Company’s expected milestones for 2024, and the Company’s beliefs and expectations regarding the sufficiency of its existing cash and cash equivalents to fund its planned operatings, its ability to raise additional funds, which may not be available to the Company on acceptable terms or at all, its ability to resume development of GRI-0863 and capital expenditure requirements. Actual results may differ from the forward-looking statements expressed by the Company in this press release and consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, without limitation: (1) the inability to maintain the listing of the Company’s common stock on Nasdaq and to comply with applicable listing requirements; (2) changes in applicable laws or regulations; (3) the inability of the Company to raise financing in the future; (4) the success, cost and timing of the Company’s product development activities; (5) the inability of the Company to obtain and maintain regulatory clearance or approval for its respective products, and any related restrictions and limitations of any cleared or approved product; (6) the inability of the Company to identify, in-license or acquire additional technology; (7) the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently developing; (8) the size and growth potential of the markets for the Company’s products and services, and their respective ability to serve those markets, either alone or in partnership with others; (9) the failure to achieve any milestones or receive any milestone payments under any agreements; (10) inaccuracy in the Company’s estimates regarding expenses, future revenue, capital requirements and needs for and the ability to obtain additional financing; (11) the Company’s ability to protect and enforce its intellectual property portfolio, including any newly issued patents; and (12) other risks and uncertainties indicated from time to time in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including the risks and uncertainties described in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K filed with the SEC on March 28, 2024 and subsequently filed reports. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
GRI@jtcir.com
1 T. M. Maher et al., Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res 22, 197 (2021)
FAQ
What is GRI Bio's lead program for treating Idiopathic Pulmonary Fibrosis (IPF)?
When is GRI Bio (GRI) expecting to report data from its Phase 2a biomarker study for GRI-0621?
What are the limitations of current Idiopathic Pulmonary Fibrosis (IPF) treatments that GRI Bio (GRI) is trying to address?
Who participated in the Virtual Investor KOL Connect segment for GRI Bio (GRI)?
